NicOx SA (NCOX.F) NCX 1510 Partnered With Biolipox AB Demonstrates Rapid Relief In New Clinical Trial
10/19/2005 5:12:47 PM
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Feb. 22, 2005--NicOx S.A. (Eurolist: NICOX) informs you that its partner, Biolipox AB, issued a press release today announcing that a new clinical study of NCX 1510, in development for the treatment of rhinitis, has demonstrated an onset of action of only 5-10 minutes. These new results follow the announcement in June 2004, that NCX 1510 had reached the primary efficacy endpoint of a Phase IIa study in patients suffering from allergic rhinitis. NCX 1510 is the first compound to be selected from the ongoing research and co-development agreement between NicOx and Biolipox for the discovery and development of novel compounds in the respiratory field.